Get started
Author

Shuichi Takahashi

Observed institution: Takara BIO Inc. (Japan)
ORCID: 0009-0001-2340-5049
Observed ORCID: 0009-0001-2340-5049
OpenAlex ID: A5064417278
Safety and Efficacy of NY-ESO-1 Antigen-Specific T-Cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I/II Clinical Trial
2023 · Akira Kawai, Mikiya Ishihara, et al. · Clinical Cancer Research · 37
PDF
Position measuring device
1998 · Kazuyuki Maeda, Shuichi Takahashi, et al. · 2
Supplementary Table S6 from Safety and Efficacy of NY-ESO-1 Antigen-Specific T-Cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I/II Clinical Trial
2023 · Akira Kawai, Mikiya Ishihara, et al.
PDF
Supplementary Table S6 from Safety and Efficacy of NY-ESO-1 Antigen-Specific T-Cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I/II Clinical Trial
2023 · Akira Kawai, Mikiya Ishihara, et al.
Supplementary Figure S1 from Safety and Efficacy of NY-ESO-1 Antigen-Specific T-Cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I/II Clinical Trial
2023 · Akira Kawai, Mikiya Ishihara, et al.
PDF
Supplementary Table S7 from Safety and Efficacy of NY-ESO-1 Antigen-Specific T-Cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I/II Clinical Trial
2023 · Akira Kawai, Mikiya Ishihara, et al.
Supplementary Table S5 from Safety and Efficacy of NY-ESO-1 Antigen-Specific T-Cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I/II Clinical Trial
2023 · Akira Kawai, Mikiya Ishihara, et al.
Supplementary Table S3 from Safety and Efficacy of NY-ESO-1 Antigen-Specific T-Cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I/II Clinical Trial
2023 · Akira Kawai, Mikiya Ishihara, et al.
PDF
Supplementary Table S4 from Safety and Efficacy of NY-ESO-1 Antigen-Specific T-Cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I/II Clinical Trial
2023 · Akira Kawai, Mikiya Ishihara, et al.
Supplementary Table S2 from Safety and Efficacy of NY-ESO-1 Antigen-Specific T-Cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I/II Clinical Trial
2023 · Akira Kawai, Mikiya Ishihara, et al.
Supplementary Table S1 from Safety and Efficacy of NY-ESO-1 Antigen-Specific T-Cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I/II Clinical Trial
2023 · Akira Kawai, Mikiya Ishihara, et al.
Supplementary Table S8 from Safety and Efficacy of NY-ESO-1 Antigen-Specific T-Cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I/II Clinical Trial
2023 · Akira Kawai, Mikiya Ishihara, et al.
Supplementary Table S2 from Safety and Efficacy of NY-ESO-1 Antigen-Specific T-Cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I/II Clinical Trial
2023 · Akira Kawai, Mikiya Ishihara, et al.
PDF
Supplementary Table S8 from Safety and Efficacy of NY-ESO-1 Antigen-Specific T-Cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I/II Clinical Trial
2023 · Akira Kawai, Mikiya Ishihara, et al.
PDF
Supplementary Figure S1 from Safety and Efficacy of NY-ESO-1 Antigen-Specific T-Cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I/II Clinical Trial
2023 · Akira Kawai, Mikiya Ishihara, et al.
Data from Safety and Efficacy of NY-ESO-1 Antigen-Specific T-Cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I/II Clinical Trial
2023 · Akira Kawai, Mikiya Ishihara, et al.
Works count: 16
Citation count: 39
H-index: 2
I10-index: 1
Year
Topic
Type